biolitec AG: biolitec AG increases group revenue to 29.4 million Euros in the first three quarters of 2011/12 - cost of sales rises to more than 9 million Euros

biolitec AG  / Key word(s): Interim Report/Interim Report

22.08.2012 15:47

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

biolitec AG increases group revenue to 29.4 million Euros in the first
three quarters of 2011/12 - cost of sales rises to more than 9 million
Euros

Jena, 22th August 2012 - biolitec AG (ISIN DE0005213409), Jena, listed on
the Prime Standard of the Frankfurt Stock Exchange, achieved group sales of
29.4 million Euros in the first three quarters of the 2011/12 fiscal year.
Thus, sales increased by approximately 3.3 million Euros compared to the
same period in the previous fiscal year. The growth in sales is
attributable to the rising demand for biolitec treatments; for example, for
the benign prostate hyperplasia (LIFE(TM)), the endoluminal laser treatment
for veins (ELVeS(TM)) and the new HeLP(TM) (Haemorrhoid Laser Procedure)
treatment for the atrophy of haemorrhoidal arteries.

Expenses relating to Research & Development for the first three quarters of
the 2011/12 fiscal year for an amount of 3.18 million Euros (approximately
10.8% of sales) reached the previous year's level. The cost of sales has
increased to 9.13 million Euros (compared to 8.04 million Euros in the same
period of the previous year).

The gross profit of 18.56 million Euros has remained at the level of the
previous year (previous year: 18.59 million Euros) and the Earnings Before
Interest and Tax (EBIT) declined to 1.29 million Euros (previous year: 1.49
million Euros).

Significant revenues of biolitec AG were achieved in Europe and North
America. With 10.8 million Euros, the sales in North America were 14%
higher than those in the previous fiscal year. The sales in Europe reached
11.9 million Euros (previous fiscal year: 11.8 million Euros). biolitec
AG's subsidiaries abroad, particularly in the Middle East and in Asia,
delivered sales figures that showed gratifying growth rates of 37%
(reaching 6.7 million Euros) as compared to the first three quarters of the
previous year. biolitec's medium-term goal is to increase the share of
revenue in these markets to one-third of sales and thus to generate further
growth.

The sales figure for the Meditec segment was 28.3 million Euros in the
first three quarters, in the pharmaceuticals segment sales were 1.1 million
Euros.

biolitec has decided to publish its results for the first three quarters of
2011/12 even though the annual statement of accounts for 2010/11 has not
yet been audited (the unaudited sales figure for which was 35.24 million
Euros). The tentative sales figures for the 2011/12 fiscal year for the
biolitec group are pegged at 40.27 million Euros.

In the meantime, biolitec has decided to relocate its registered office to
Austria. In the course of the merger, the biolitec share shall be exchanged
into new shares to the Entry Standard. Thus, continuous trading of the
shares in the quality segment Entry Standard of the Frankfurt Stock
Exchange shall be ensured for the shareholders. The listing in the Entry
Standard of the Frankfurt Stock Exchange requires less regulatory effort
and saves costs for the company.

To combine the transfer to Vienna with the already announced changeover to
the Entry Standard, BioMed Technology Investment Holding as major
shareholder with slightly more than 75% of the voting rights in biolitec AG
has already announced to vote for the merger with biolitec AG's Austrian
subsidiary at the Extraordinary General Meeting of biolitec AG. The
acceptance of a corresponding request is therefore ensured.

For the coming fiscal year 2012/13, biolitec expects growth to be
sustained.


22.08.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      biolitec AG
              Otto-Schott-Str.15
              07745 Jena
              Germany
Phone:        +49 (0) 3641 519 53 0
Fax:          +49 (0) 3641 519 53 33
E-mail:       info@biolitec.de
Internet:     www.biolitec.de
ISIN:         DE0005213409
WKN:          521340
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------